Sorafenib and radiation therapy for the treatment of advanced hepatocellular carcinoma

被引：19

作者：

Anne M. Horgan

Laura A. Dawson

Anand Swaminath

Jennifer J. Knox

机构：

[1] Medical Oncology, Princess Margaret Hospital, Toronto

来源：

Journal of Gastrointestinal Cancer | 2012年 / 43卷 / 2期

关键词：

Hepatocellular carcinoma; Radiation therapy; Sorafenib;

D O I：

10.1007/s12029-010-9194-4

中图分类号：

学科分类号：

摘要：

Introduction: Treatment options for advanced hepatocellular cancer (HCC) are limited. Sorafenib, an orally active multi-kinase inhibitor, is the only systemic agent with a survival benefit in randomized studies. However, the gain in survival is modest and new treatment strategies are needed. Clinical cases: We report two cases of advanced HCC treated with a combination of sorafenib and radiation therapy. Impressive and sustained clinical and radiological responses were seen. Treatment was well-tolerated in both cases with no unexpected toxicities reported. Discussion: There is sound rationale for the combination of sorafenib and radiation therapy for treatment of HCC. These two cases suggest both feasibility and efficacy of this combination, in selected patients. Prospective studies addressing this combination are ongoing. © Springer Science+Business Media, LLC 2010.

引用

页码：344 / 348

页数：4

共 17 条

[1]

Llovet J.M., Ricci S., Mazzaferro V., Hilgard P., Gane E., Blanc J.F., Et al., Sorafenib in advanced hepatocellular carcinoma, N Engl J Med, 359, 4, pp. 378-390, (2008)

[2]

Wilhelm S.M., Carter C., Tang L., Wilkie D., McNabola A., Rong H., Chen C., Zhang X., Vincent P., McHugh M., Cao Y., Shujath J., Gawlak S., Eveleigh D., Rowley B., Liu L., Adnane L., Lynch M., Auclair D., Taylor I., Gedrich R., Voznesensky A., Riedl B., Post L.E., Bollag G., Trail P.A., BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis, Cancer Research, 64, 19, pp. 7099-710

[3]

Hsu W.C., Chan S.C., Ting L.L., Chung N.N., Wang P.M., Ying K.S., Et al., Results of three-dimensional conformal radiotherapy and thalidomide for advanced hepatocellular carcinoma, Jpn J Clin Oncol, 36, 2, pp. 93-99, (2006)

[4]

Ben-Josef E., Normolle D., Ensminger W.D., Walker S., Tatro D., Ten H.R.K., Knol J., Dawson L.A., Pan C., Lawrence T.S., Phase II trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies, Journal of Clinical Oncology, 23, 34, pp. 8739-8747, (2005)

[5]

Mornex F., Girard N., Beziat C., Kubas A., Khodri M., Trepo C., Merle P., Feasibility and efficacy of high-dose three-dimensional-conformal radiotherapy in cirrhotic patients with small-size hepatocellular carcinoma non-eligible for curative therapies-mature results of the French Phase II RTF-1 trial, International Journal of Radiation Oncology Biology Physics, 66, 4, pp. 1152-1158, (2006)

[6]

Seong J., Shim S.J., Lee I.J., Han K.H., Chon C.Y., Ahn S.H., Evaluation of the prognostic value of Okuda, Cancer of the Liver Italian Program, and Japan Integrated Staging systems for hepatocellular carcinoma patients undergoing radiotherapy, Int J Radiat Oncol Biol Phys, 67, 4, pp. 1037-1042, (2007)

[7]

Kim T.H., Kim D.Y., Park J.-W., Kim Y.I., Kim S.H., Park H.S., Lee W.J., Park S.J., Hong E.K., Kim C.-M., Three-dimensional conformal radiotherapy of unresectable hepatocellular carcinoma patients for whom transcatheter arterial chemoembolization was ineffective or unsuitable, American Journal of Clinical Oncology: Cancer Clinical Trials, 29, 6, pp. 568-575, (2006)

[8]

Liu M.-T., Li S.-H., Chu T.C., Hsieh C.-Y., Wang A.-Y., Chang T.-H., Pi C.-P., Huang C.-C., Lin J.-P., Three-dimensional conformal radiation therapy for unresectable hepatocellular carcinoma patients who had failed with or were unsuited for transcatheter arterial chemoembolization, Japanese Journal of Clinical Oncology, 34, 9, pp. 532-539, (2004)

[9]

Park W., Lim D.H., Paik S.W., Koh K.C., Choi M.S., Park C.K., Yoo B.C., Lee J.E., Kang M.K., Park Y.J., Nam H.R., Ahn Y.C., Huh S.J., Local radiotherapy for patients with unresectable hepatocellular carcinoma, International Journal of Radiation Oncology Biology Physics, 61, 4, pp. 1143-1150, (2005)

[10]

Tse R.V., Hawkins M., Lockwood G., Kim J.J., Cummings B., Knox J., Sherman M., Dawson L.A., Phase I study of individualized stereotactic body radiotherapy for hepatocellular carcinoma and intrahepatic cholangiocarcinoma, Journal of Clinical Oncology, 26, 4, pp. 657-664, (2008)

← 1 2 →